NORCROSS, Ga.--(BUSINESS WIRE)--A non-invasive device being developed by SpectRx, Inc. (OTCBB: SPRX) to detect cervical cancer and precancer could reduce unnecessary biopsies by 55% while accurately detecting disease, according to results of a study published in the January edition of the Journal of Lower Genital Tract Disease. The device, in FDA pivotal clinical trials at five sites, is simple to use and was “well accepted” by subjects, according to the study.
